Abbott (NYSE: ABT) director Darren McDew receives 2,286-share RSU award

Rhea-AI Filing Summary

McDew Darren W reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories director Darren W. McDew received an equity award of 2,286 common shares-equivalent on a grant/award basis. The award is structured as a restricted stock unit grant under the Abbott Laboratories 2026 Incentive Stock Program and carries no cash purchase price.

The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, McDew directly holds 12,678 common shares, reflecting routine director compensation rather than an open-market share purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McDew Darren W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	--

Holdings After Transaction: Common shares without par value — 12,678 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 2,286 shares Transaction price per share: $0.00 Shares held after grant: 12,678 shares +1 more

4 metrics

RSU grant size 2,286 shares Restricted stock unit award on 2026-04-24

Transaction price per share $0.00 Grant/award acquisition, not open-market purchase

Shares held after grant 12,678 shares Direct ownership following reported transaction

Transaction date 2026-04-24 Date of restricted stock unit grant

Key Terms

Restricted stock unit award, 2026 Incentive Stock Program, change in control

3 terms

Restricted stock unit award financial

"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

2026 Incentive Stock Program financial

"granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"

change in control financial

"the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McDew Darren W

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	04/24/2026		A		2,286(1)	A	$0	12,678	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ Darren W. McDew by Jessica H. Paik, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Abbott Laboratories (ABT) director Darren W. McDew report on this Form 4?

Darren W. McDew reported receiving an equity grant of 2,286 Abbott common shares-equivalent. The award is a restricted stock unit grant under Abbott’s 2026 Incentive Stock Program and is part of his director compensation, not an open-market stock purchase.

Is Darren W. McDew buying or selling Abbott (ABT) shares in this filing?

He is not buying or selling in the market; he is receiving a grant. The 2,286-share award is a restricted stock unit grant with a zero purchase price, representing compensation rather than a discretionary open-market trade by the director.

When will Darren W. McDew receive the Abbott (ABT) shares from this RSU award?

The award will be paid in Abbott common shares on a one-to-one basis. Payment occurs at the earlier of his separation from service, death, or a change in control, as defined in Abbott’s 2026 Incentive Stock Program.

How many Abbott (ABT) shares does Darren W. McDew hold after this transaction?

After this grant, Darren W. McDew directly holds 12,678 Abbott common shares. This total includes the impact of the 2,286-share restricted stock unit grant reported in the filing, reflecting his updated direct ownership position as a director.

What is the transaction price for Darren W. McDew’s Abbott (ABT) equity award?

The reported transaction price per share is $0.00 because the 2,286-share award is a restricted stock unit grant. It is issued as compensation under Abbott’s 2026 Incentive Stock Program rather than purchased for cash on the open market.